Hillhurst Biopharmaceuticals, Inc. — Biomedical Watch V2

Traitements2programmes

Essais1liés

Publications2liées

SourceDBlocale

Traitements

2

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
HBI-002A phase 2a multicenter, randomized, double-blind, placebo-controlled multiple dose study to evaluate the safety, tolerability, pharmacokinetics, of HBI-002, an oral low-dose carbon monoxide (CO) liquid drug product, administered daily over 14 days in subjects with Parkinson's disease (PD).	Parkinson	Phase 2	À vérifier	United States	À vérifier
HBI-002A phase 2a multicenter, randomized, double-blind, placebo-controlled multiple dose study to evaluate the safety, tolerability, pharmacokinetics, of HBI-002, an oral low-dose carbon monoxide (CO) liquid drug product, administered daily over 14 days in subjects with Parkinson's disease (PD).	Parkinson	Phase 2	À vérifier	United States	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
HBI-002	Parkinson	Phase 2	NCT07005180	LoCaMoTE-PD — Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease	RECRUITING

Publications

2

Molécule	Indication / population	Titre	Journal	Date
HBI-002		Oral carbon monoxide therapy in murine sickle cell disease: Beneficial effects on vaso-occlusion, inflammation and anemia.	PloS one
HBI-002		Beneficial Effects of Oral Carbon Monoxide on Doxorubicin-Induced Cardiotoxicity.	Journal of the American Heart Association